DexCom reported a strong Q1 2026 with 15% revenue growth, record global new patient starts, and significant margin expansion. Management reaffirmed revenue guidance while raising operating margin guidance, driven by operational efficiencies and the successful G7 15-day launch, despite geopolitical uncertainties. Key catalysts include expansion of type 2 non-insulin coverage and upcoming RCT results. Q1 revenue of $1.19B (+15% reported, +12% organic), U.S. +11%, International +26% (organic +17%).
DexCom reported a strong Q1 2026 with 15% revenue growth, record global new patient starts, and significant margin expansion. Management reaffirmed revenue guidance while raising operating margin guidance, driven by operational efficiencies and the successful G7 15-day launch, despite geopolitical uncertainties. Key catalysts include expansion of type 2 non-insulin coverage and upcoming RCT results. Q1 revenue of $1.19B (+15% reported, +12% organic), U.S. +11%, International +26% (organic +17%).
Management expressed confidence in continued momentum, citing record global patient starts, significant coverage wins, and a strong product pipeline, while reiterating guidance.
Q1 revenue of $1.19B (+15% reported, +12% organic), U.S. +11%, International +26% (organic +17%).
Achieved record global new patient starts; U.S. close to record.
Reported gross margin was 62.95%, reinforcing the quarter's better-than-guided profitability.
Global record patient starts in Q1. Management expressed confidence in continued momentum, citing record global patient starts, significant coverage wins, and a strong product pipeline, while reiterating guidance.
Management highlighted progress on manufacturing efficiencies and the ramp of the Ireland facility, which will increase operating expense investment in Q2 and Q3 ahead of its Q4 turn-on. They also discussed ongoing investment in automation and precision at their Mesa facility.
Management expressed confidence in continued momentum, citing record global patient starts, significant coverage wins, and a strong product pipeline, while reiterating guidance.
“nearly 50% will be converted by the end of the year over to this new 15-day product”
“There's probably about 50 to 100 basis points of potential risk associated with fuels and resins over the course of the year.”
“we expect this trial can become the defining study for the non-insulin population”
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| Gross margin | FY2026 | 63%–64% | 63.5% | MAINTAINED |
| Op margin | FY2026 | 23%–23.5% | 23.25% | RAISED |
| Revenue | FY2026 | $5.16B–$5.25B | $5.205B | MAINTAINED |